22/12/2014 14:39:18 Free Membership Login

Dr. Reddy's Launches Debiopharm's Pamorelin® LA in India for the Treatment of Locally Advanced or Metastatic, Hormone-Depend...

Date : 12/07/2012 @ 1:30PM
Source : PR Newswire (US)
Stock : DR. Reddys Laboratories Ltd. (RDY)
Quote : 50.19  0.0 (0.00%) @ 12:35PM
DR. Reddys Lab share price Chart

Dr. Reddy's Launches Debiopharm's Pamorelin® LA in India for the Treatment of Locally Advanced or Metastatic, Hormone-Depend...

DR. Reddys Lab (NYSE:RDY)
Historical Stock Chart

3 Years : From Dec 2011 to Dec 2014

Click Here for more DR. Reddys Lab Charts.
Dr. Reddy's Launches Debiopharm's Pamorelin® LA in India for the Treatment of Locally Advanced or Metastatic, Hormone-Dependent Prostate Cancer

LAUSANNE, Switzerland, December 7, 2012 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, announces that Dr. Reddy's Laboratories Ltd. launched Pamorelin® LA in India for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer on December 3.

Under the terms of the agreement, Dr. Reddy's acquires exclusive marketing and sales rights for Pamorelin® LA Depot in India. The product is exported in bulk from Debio Recherche Pharmaceutique (Debio R.P.) to Dr. Reddy's. Pamorelin® LA will be made available primarily to urologists and oncologists across India.

'We recognise the need for prostate cancer treatment in India and are thrilled to have the opportunity to bring Pamorelin® LA to Indian patients', said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™. 'This major step enables us to implement our strategy in one of the most important markets in Asia. This is only the logical continuation to a harmonious working relationship shared with Dr. Reddy's over the years.' Dr. Reddy's and Debiopharm share the same vision to bring high-quality and safe ethical products to the highest number of patients suffering from serious diseases in India.

About Pamorelin® LA (active ingredient: triptorelin)

Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). In 1982, Debiopharm signed a licensing agreement for triptorelin with Tulane University in the US. Debiopharm has then developed three slow-release formulations (1, 3 and 6 months) of triptorelin pamoate. The 1- and 3-month-formulations have been registered in most countries and are currently available under the names of Trelstar® in North America, Decapeptyl® /Pamorelin® in Europe and Latin America and from now on, of Pamorelin® in India. The 6-month-formulation has been registered and is available in Europe and the US.

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group™, please visit: http://www.debiopharm.com.

About Debio R.P.

Debio Recherche Pharmaceutique (Debio R.P.), based in Martigny (Switzerland), is a pharmaceutical research, development and production company that has been Swissmedic and ANVISA (Brazil) certified, as well as inspected and registered by the American Food and Drug Administration (FDA) and the KFDA (South Korea). Debio R.P. is active in the discovery, formulation and development of peptides. Debio R.P. forms part of Debiopharm Group™ and employs 130 people, half of whom are university graduates or engineers.

About Dr. Reddy's 

Dr. Reddy's Laboratories Ltd. (NYSE: RDY) (Dr. Reddy's) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand.

For more information, log on to: http://www.drreddys.com

Debiopharm S.A. Contact
Maurice Wagner
Director Corporate Affairs & Communication
Tel.: +41(0)21-321-01-11
Fax: +41(0)21-321-01-69
mwagner@debiopharm.com

Dr. Reddy' s Contact
S. Rajan
rajans@drreddys.com
Tel.: +91-40-49002445
Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel.: +44(0)20-7379-5151
bhudspith@maitland.co.uk

In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel.: +1-212-845-4292
Fax: +1-212-845-4260
martina.schwarzkopf@russopartnersllc.com

Investors and Financial Analysts:
Kedar Upadhye
kedaru@drreddys.com
Tel.: +91-40-66834297

Saunak Savla
saunaks@drreddys.com
Tel.: +91-40-49002135

Milan Kalawadia (USA)
mkalawadia@drreddys.com
Tel.: +1-908-203-4931


SOURCE The Debiopharm Group

Copyright 2012 PR Newswire



Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 in 141222 14:39